All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CAR T-Cell Therapy Leads to Shorter Hospital Stays, Lower Nonpharmacy Costs Despite High Overall Cost

April 7th 2023

CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them.

Nuances in SORAYA Data Highlight Role of Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer

April 7th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses a subgroup analysis of the SORAYA trial, which was presented during the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, and where the field is headed in attempt to address unmet needs for this patient population.

Effective Detection of MRD May Support Earlier Implementation of ctDNA Testing in CRC

April 6th 2023

Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.

FDA Fast Tracks CB-011 for Relapsed/Refractory Multiple Myeloma

April 6th 2023

The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.

Dostarlimab Plus Chemotherapy Shows Survival Benefit, Fills Unmet Need for Patients With Recurrent Endometrial Cancer

April 6th 2023

Combining the immune checkpoint inhibitor dostarlimab-gxly with standard-of-care chemotherapy elicited an increase in progression-free survival rates compared with chemotherapy alone for patients with primary advanced or recurrent endometrial cancer.

Recent Approvals Support Continued Research on New and Emerging ADCs Across Breast Cancer Subtypes

April 6th 2023

Stephanie L. Graff, MD, gives an overview of recently approved ADCs in TNBC and HR-positive, HER2-negative breast cancer, as well as the importance of continued research with these agents in the first-line setting.

Florida Cancer Specialists & Research Institute Shares Advances In Oncology Pharmacy Services at NCODA Global Gathering

April 6th 2023

Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute will join with colleagues this week to share the latest advances in oncology pharmacy operations and dispensing practices at the NCODA 2023 Spring Forum in Indianapolis.

FDA Grants Fast Track Designation to SynKIR-110 for Mesothelioma

April 6th 2023

The FDA has granted a fast track designation to SynKIR-110 for the treatment of patients with mesothelioma.

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML

April 6th 2023

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Second-Line Liposomal Irinotecan Fails to Improve OS, PFS Over Topotecan in SCLC

April 6th 2023

Single-agent liposomal irinotecan resulted in a similar median overall survival and progression-free survival to that achieved with topotecan in patients with small cell lung cancer that had progressed on or following frontline platinum-based chemotherapy.

Cemiplimab With or Without Chemotherapy Provides Long-Term Clinical Benefit in Locally Advanced NSCLC

April 5th 2023

First-line cemiplimab monotherapy or in combination with platinum-based chemotherapy conferred long-term clinical benefit to patients with unresectable, locally advanced non–small cell lung cancer who were ineligible for concurrent chemoradiation.

Venetoclax Induces Notable ORR But Short PFS in High-Risk Mantle Cell Lymphoma

April 5th 2023

Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.

Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL

April 5th 2023

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.

Sox9 Protein Enables Molecular Time Travel That Can Lead to Colorectal Cancer

April 5th 2023

Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer

April 5th 2023

The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Durvalumab Regimen With Maintenance Olaparib Combo Improves PFS in Select High-Grade Epithelial Ovarian Cancer

April 5th 2023

Induction therapy with durvalumab plus chemotherapy and bevacizumab, followed by maintenance with olaparib plus durvalumab and bevacizumab, elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy plus bevacizumab in patients with newly diagnosed advanced high-grade epithelial ovarian cancer who did not harbor BRCA mutations.

Not All Stage I and II Endometrial Cancers Are Alike

April 5th 2023

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

Investigators Turn a Focused Eye to Targeting Weaknesses in BPDCN

April 5th 2023

Because of the disease’s rarity relative to other hematologic malignancies and challenges arriving at an accurate diagnosis, patients with blastic plasmacytoid dendritic cell neoplasm have historically encountered a dearth of effective treatment options.

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

April 4th 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Atezolizumab Following Neoadjuvant Atezolizumab and Resection Improves DFS in NSCLC

April 4th 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.